This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...

Eli Lilly trades near historical P/E means of ~30x with a 3Y PEG of 1.13x, offering attractive long-term upside potential. Click here to read why LLY is a Buy.

Adults with obesity may now move directly from Wegovy 2.4mg to 7.2mg if they need greater weight loss ...

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings preview.

With their blockbuster obesity drugs, Eli Lilly and Novo Nordisk have uncovered a variety of ailments the incretin treatments can combat. | Six weeks after Eli Lilly revealed the success of phase 3b ...

A new overview details emerging medical and wellness trends, underscoring advances that broaden treatment access and inform preventive care. GLP-1 drugs such as Ozempic and Wegovy extend to heart, ...

My son is smart - he really is - but he was in love. He and his live-in girlfriend mingled their finances. I'm not sure how much, but now that they've parted, his credit rating is wrecked. Just enough ...

A new study confirms that people taking GLP-1s are more likely to experience hair loss. The good news? It’s probably reversible. Here’s how to deal.

A new review finds no convincing evidence that drugs like Ozempic raise people's risk of common thyroid cancers.

In an interview with The American Journal of Managed Care®, Levin explained that for patients whose medications are covered ...

Insurers cite unsustainable costs as GLP-1 benefits disappear, accelerating a national shift in employer-sponsored ...